Connect with us
MARE BALTICUM Gaming & TECH Summit 2024

Artificial Intelligence

Steven Mah, Ph.D., Joins Cowen’s Equity Research Team to Cover Life Science & Diagnostic Tools

Published

on

NEW YORK, Feb. 03, 2022 (GLOBE NEWSWIRE) — Cowen Inc. (NASDAQ:COWN) (“Cowen” or the “Company”) today announced that Steven Mah, Ph.D., has joined the Company’s equity research team to further expand the firm’s coverage of the life science & diagnostic tools sector. He will be based in New York, and will report to Robert Fagin, Cowen’s Head of Research.

“Cowen continues to build its market-leading life science & diagnostic tools franchise,” said Mr. Fagin. “Steve’s expertise in dynamic emerging market segments such as synthetic biology and artificial-intelligence driven health solutions will further differentiate our coverage.”

Cowen’s acclaimed research department consists of 61 senior analysts covering over 975 securities across multiple sectors, including health care, consumer, energy, sustainability and energy transition, technology media & telecom, capital goods & industrials, and Washington policy.

Prior to joining Cowen, Dr. Mah was a senior analyst for life science & diagnostic tools at Piper Sandler, and earlier in his career was a Principal in Piper Sandler’s health care investment banking group, where he focused on mergers and acquisitions as well as equity and equity-linked transactions. Dr. Mah holds a B.S. in molecular biology from the University of California, Los Angeles; a Ph.D. in molecular biology from the University of California, San Diego; and an MBA from Cornell University’s Johnson Graduate School of Management.

About Cowen Health Care Research

  • With 18 senior analysts, Cowen has one of the largest health care research footprints on Wall Street.
  • The team includes two analysts in Cowen’s Washington Research Group focused exclusively on health care policy. This effort complements, and is integrated with, the firm’s fundamental analysis.
  • Cowen’s health care analysts are consistently ranked among the best in third-party polls such as Institutional Investor magazine’s All-America Research Team and the Refinitiv StarMine Analyst Awards.
  • The team boasts a long tradition of collaboration and thought leadership. Marquee publications such as Cowen’s Biotech Quarterly, Therapeutics Categories, and annual drug pricing survey have been widely read, and published consistently, for more than 25 years. Other major publications include Pharmaceutical Industry Pulse, Specialty Pharmaceutical Industry Pulse, and Life Science Tool Kit.
  • The research team also publishes numerous studies under Cowen’s flagship Ahead of the Curve® Series banner. Recent reports have included in-depth explorations of gene editing, next-generation proteomics tools, and emerging hematology-oncology treatments.
  • The Company hosts some of the longest-running and best attended events in the sector, including Cowen’s Health Care Conference (now in its 42nd year); the Therapeutics Conference (now in its 25th year); the MedTools Conference (now in its 11th year); and the FutureHealth Conference (now in its 7th year). Cowen also hosts numerous targeted events, including Cowen’s Gene Therapy Summit, Oncology Innovation Summit, and Psychedelics & Novel Mechanisms in Neuropsychiatry Summit.

About Cowen Inc.
Cowen Inc. (“Cowen” or the “Company”) is a diversified financial services firm that operates through two business segments: a broker dealer and an investment management division. The Company’s broker dealer division offers investment banking services, equity and credit research, sales and trading, prime brokerage, global clearing and commission management services. Cowen’s investment management segment offers actively managed alternative investment products. Cowen Inc. focuses on delivering value-added capabilities to our clients in order to help them outperform. Founded in 1918, the firm is headquartered in New York and has offices worldwide. Learn more at Cowen.com.

© 2022, COWEN INC., ALL RIGHTS RESERVED. COWEN AND COMPANY, LLC: MEMBER FINRA, NYSE AND SIPC 

MEDIA CONTACT
Gagnier Communications
Dan Gagnier
[email protected]
646 569 5897

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Artificial Intelligence

oToBrite Develops a Compact All-Weather Vision-AI Driver Monitoring System for the Commercial Vehicle Market

Published

on

otobrite-develops-a-compact-all-weather-vision-ai-driver-monitoring-system-for-the-commercial-vehicle-market

HSINCHU, May 9, 2024 /PRNewswire/ — oToBrite, a leading provider of vision-AI ADAS solutions, has successfully developed a compact all-weather vision-AI Driver Monitoring System (DMS). With a high-sensitivity automotive-grade global shutter image sensor, the system achieves outstanding Quantum Efficiency (QE), providing clear image quality day and night. With oToBrite’s proprietary secondary optical system, the overall combination effectively enhances the accuracy and reliability of the vision-AI algorithm in all weather conditions. The DMS has already been successfully delivered to heavy commercial vehicle manufacturers, mitigating the potential risks of traffic accidents.

oToBrite’s vision-AI DMS utilizes self-developed AI 3D facial landmark technology to identify over 100 driver IDs and recognize driving behaviors, including smoking, phone use, distraction, fatigue. The system remains effective even when drivers wear Level 3 sunglasses or coated glasses, without compromising the detection and recognition capabilities of vision-AI.
The vision-AI DMS features a 940nm infrared and high-QE sensor, coupled with oToBrite’s proprietary optical design, ensuring clear images in strong light conditions (>120K lux) or during nighttime driving. Additionally, oToBrite’s vision-AI technology optimizes facial image quality, ensuring accurate AI recognition whether driving against sunlight, backlight, or through tunnels.
Miniaturization is a significant trend in driver monitoring applications. oToBrite further emphasizes that, compared to many systems on the market requiring multiple LEDs for sufficient illumination, the DMS only needs one LED to meet the system’s image quality requirements. In terms of hardware technology, oToBrite’s secondary optical system adjusts the LED light source to any angle to meet light distribution needs. Concentrating the light source can double the illumination, producing more reliable images for AI recognition. This also reduces optical component usage, enhances image clarity, and saves installation space and system costs.
According to the 2023 market research report by Gii, the DMS market reached $1.3 billion in 2022, with an expected Compound Annual Growth Rate (CAGR) of 8.3% by 2028, reaching $20.8 billion. Currently, several countries are drafting or have implemented regulations, and driven by regulatory demand, oToBrite’s compact all-weather vision-AI DMS has begun mass production, contributing to achieving Vision Zero. Read more: http://www.otobrite.com/en/block/index/99
About oToBrite 
oToBrite is a leading vison-AI ADAS/AD solutions provider. Based in Hsinchu Science Park, oToBrite has IATF 16949-certified clean room factory and many years of experience as an automotive Tier-1 supplier. Through comprehensive research and development capabilities, oToBrite provides vision-AI algorithms, ECU/domain controllers and automotive-grade/special purpose cameras.
Photo – https://mma.prnewswire.com/media/2406494/News_DMS0507.jpg

View original content:https://www.prnewswire.co.uk/news-releases/otobrite-develops-a-compact-all-weather-vision-ai-driver-monitoring-system-for-the-commercial-vehicle-market-302140971.html

Continue Reading

Artificial Intelligence

OMRON Selects IPfolio from Clarivate

Published

on

omron-selects-ipfolio-from-clarivate

IP solution maximizes operational efficiency for leading automation company
LONDON, May 9, 2024 /PRNewswire/ — Clarivate Plc (NYSE: CLVT), a leading global provider of transformative intelligence, announced today that OMRON has selected IPfolio™, an intellectual property management software from Clarivate to transform their IP operations. This solution will enable OMRON, a leading automation company to make smarter decisions and plan strategically using IP data and analytical insights.

With IPfolio’s help, OMRON will be able to better manage its IP assets and keep up with the rising number of filings and data volumes, while eliminating manual processes. The IP team at OMRON can enhance their analysis and collaboration with stakeholders by using insightful data visualizations. This can lead to increased productivity, deeper insights, and faster decision-making with confidence.
Gordon Samson, President, Intellectual Property, Clarivate, said, “Our IP Management Software integrates data and services to empower our clients to remove friction, enhance collaboration and make better informed decisions. We are confident that IPfolio will help OMRON simplify the process of managing IP assets across the entire lifecycle.”
About ClarivateClarivate™ is a leading global provider of transformative intelligence. We offer enriched data, insights & analytics, workflow solutions and expert services in the areas of Academia & Government, Intellectual Property and Life Sciences & Healthcare. For more information, please visit www.clarivate.com
Media Contact:Jack Wan, External Communications [email protected]
Logo – https://mma.prnewswire.com/media/1159266/Clarivate_Logo.jpg

View original content:https://www.prnewswire.co.uk/news-releases/omron-selects-ipfolio-from-clarivate-302139322.html

Continue Reading

Artificial Intelligence

First-of-Its-kind Institute of Neurotechnology & Law Launches in the UK

Published

on

first-of-its-kind-institute-of-neurotechnology-&-law-launches-in-the-uk

Most people don’t know that, due to recent groundbreaking scientific advances, existing technology can read thoughts, implant dreams, scan memory, tell if a subject is in love, and hack brains for PIN codes.
LONDON, May 9, 2024 /PRNewswire/ — Announcing the establishment of the Institute of Neurotechnology and Law (INL) – the first organisation of its kind in the world, crafted in response to the swift advancements in neurotechnology and the emerging concerns over human rights and privacy.

The world is about to change. Yet whilst AI steals the headlines, recent extraordinary advancements in neurotechnology have gone largely under the radar.
That is why we have set up the Institute of Neurotechnology and Law.
“We are at a critical juncture in the evolution of neurotechnology. The possibilities for improving human life are immense, yet so are the risks to privacy and autonomy,” stated Founder Harry Lambert. “The Institute of Neurotechnology and Law is dedicated to ensuring these technologies enable human flourishing without compromising our moral and ethical principles.”
The institute has already garnered significant attention, attracting some of the world’s foremost experts in neurotechnology, neuroscience, ethics, and law. These distinguished panellists will collaborate to address the pressing issues at the intersection of technology and human rights, aiming to influence policy both domestically and internationally.
For more information about the Institute of Neurotechnology and Law, upcoming events, and membership details, please visit www.neurotechlaw.com.
Media Contact: [email protected]. 07982678044

View original content:https://www.prnewswire.co.uk/news-releases/first-of-its-kind-institute-of-neurotechnology–law-launches-in-the-uk-302140545.html

Continue Reading
Advertisement
Advertisement

Latest News

Trending